𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients

✍ Scribed by P. Vandel; E. Haffen; S. Nezelof; F. Broly; J. P. Kantelip; D. Sechter

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
67 KB
Volume
19
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Cytochrome P450‐2D6 may be involved in the metabolism of many drugs such as psychotropic drugs and its genetic polymorphism is responsible for inter‐individual differences in the therapeutic effect and toxicity of these drugs. Moreover with the same genetic basis, CYP2D6 metabolic capacity variations are observed. Different factors of variation may be involved, among them the prescribed drugs.

The aim of this study was to compare the influence of two types of antidepressants, tricyclic (clomipramine) and serotonergic specific recapture inhibitor (SSRI) (fluoxetine), on the CYP2D6 metabolic capacity of depressed inpatients. The CYP2D6 phenotype (dextromethorphan test) was determined in 56 genotyped (PCR‐SSCP) depressed caucasian inpatients with a heterozygous genotype. Forty‐five subjects were treated with clomipramine and eleven received fluoxetine. The dextromethorphan metabolic ratio (MR) median was significantly higher in the fluoxetine group (0.255) than in the clomipramine group (0.083, p < 0.014). In this study, fluoxetine involved a greater decrease of CYP2D6 metabolic capacity than clomipramine. Clinical implications and the possible connection between a decreased CYP2D6 activity and adverse drug effects were discussed. Caution should be taken when drugs with a low therapeutic index must be coprescribed in such patients. Copyright © 2004 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

CYP2D6 genotype and venlafaxine-XR conce
CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly
✍ Ellen M. Whyte; Marjorie Romkes; Benoit H. Mulsant; Margaret A. Kirshne; Amy E. 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB

## Abstract ## Introduction The elderly are at increased risk for medication‐related adverse events. Recent reports indicate that venlafaxine may put the elderly at increased risk of cardio‐ and cerebrovascular adverse events. We investigated the relationship between the __CYP2D6__ polymorphism an

Effects of the CYP2D6*10 alleles and co-
Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia
✍ Tatsuhiko Yagihashi; Masafumi Mizuno; Bun Chino; Yuji Sato; Kei Sakuma; Toru Tak 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB

## Abstract ## Objective Risperidone is converted to 9‐hydroxyrisperidone by CYP2D6. Two parameters were used to examine the influences of CYP2D6 polymorphism and of co‐medication on risperidone metabolism: the risperidone:9‐hydroxyrisperidone concentration ratio (R:9‐OHR ratio) and the sum of the

No evidence of increased adverse drug re
No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline
✍ Rebecca L. Roberts; Roger T. Mulder; Peter R. Joyce; Suzanne E. Luty; Martin A. 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB

## Abstract The polymorphic enzyme cytochrome P450 CYP2D6 is involved in the metabolism of many antidepressants, including nortriptyline and fluoxetine. Some 7%–10% Caucasians have inactivating mutations in both alleles of the __CYP2D6__ gene, and are referred to as poor metabolizers (PMs). Several

Effectiveness of fluoxetine and doxepin
Effectiveness of fluoxetine and doxepin in treatment of melancholia in depressed patients
✍ Paul Sandor; Brian Baker; Jane Irvine; Paul Dorian; D. McKessok; S. Mendlowitz 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 50 KB 👁 2 views

It has been suggested that serotonin reuptake inhibitors (SSRIs) may be less effective than tricyclic antidepressants (TCAs) in treatment of melancholic depression. We treated 36 depressed ambulatory patients with doxepin or fluoxetine in a double-blind, randomized 6-week trial with placebo run-in.